ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / JAGX / earnings
HIND (29) BOLT (37) BIVI (32) KTTA (40) ⌘ Pro Terminal →

Jaguar Health Inc. (JAGX) Next Earnings Date & Expected ±12.5% Move

$0.88 -45.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.81

Jaguar Health Inc. (JAGX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JAGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JAGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.88 (-45.43% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JAGX ranks #871 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JAGX compare to HIND and BOLT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while JAGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JAGX?
▼

Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.81 (-8.37%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
$1158 Bull$1 Base$1 Bear
📬 FREE JAGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JAGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY JAGX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$4.16-36.8% Next Q
Q2 (-2Q)
33
Grade E$2.63-14.8% Next Q
Q3 (-1Q)
31
Grade E$2.24-60.7% Next Q
Current
28
Grade E$0.88-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JAGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JAGX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.00) and Max Pain ($0.92) forces dealer call-delta covering toward $1,157.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JAGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JAGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.11 Expected Swing
$1.00 (-12.5%)Spot $0.88$0.99 (+12.5%)
MODEL EARNINGS SETUP GAUGE

JAGX Quantitative Pre-Earnings Setup: 28/100

Trailing EPS: $4.25 • YoY Revenue Growth: -1.5%

Model Bullish Setup (28/100)Model Risk Weight (72/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$11.5M-$54.0K-$23.7M67.2%
FY 20242024-12-31$11.7M-$39.3K-$29.4M83.3%
FY 20232023-12-31$9.8M-$41.9K-$33.2M67.2%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JAGX)

  • ✓Walkthrough of JAGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
JAGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.19%▼ DESCENDING CHANNEL
2026-11-03O $2.04H $2.04L $0.88C $0.88VOL 383.6K
RES: $39.15SUP: $-7.73SMA50: $6.00SMA200: $114.4
$726.0$529.5$332.9$136.4$-60.11RES $39.15SUP $-7.73$0.882026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JAGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JAGX Butterfly Map → + Track JAGX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JAGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JAGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JAGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JAGX)

Health Care Rank #871 of 1015 ⚔️ HIND vs JAGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JAGX vs. HIND, BOLT, BIVI, KTTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Jaguar Health Inc. (JAGX) ranks #871 by composite RQD confidence (28/100, grade E) and #869 by equity capitalization ($12.6M). Within this direct 5-issuer industry benchmark cohort, JAGX leads on earnings valuation at N/A trailing P/E, while JAGX leads on capital efficiency and profitability with -35.0% ROIC and 67.2% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JAGX at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
JAGX ACTIVE
Jaguar Health Inc.
E 28/100 — 67.2% -35.0% -45.43% $12.6M Benchmark Subject
HIND
Vyome Holdings Inc.
E 29/100 — 68.4% -35.0% -2.22% $12.6M /hind-vs-jagx →
BOLT
Bolt Biotherapeutics Inc.
D- 37/100 — — -35.0% -5.31% $12.7M /bolt-vs-jagx →
BIVI
BioVie Inc. (Class A)
E 32/100 — — -35.0% -4.20% $12.4M /bivi-vs-jagx →
KTTA
Pasithea Therapeutics Corp.
D- 40/100 — — -35.0% -0.59% $12.4M /ktta-vs-jagx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585608 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jaguar Health Inc. (JAGX) reported GAAP revenue of $11.5M (-1.5% vs. FY2024 revenue of $11.7M , and +17.9% cumulative change since FY2023) , GAAP net income of -$54.0K, operating cash flow of -$23.7M, and free cash flow of -$23.7M (+19.4% YoY). On the balance sheet, JAGX closed FY2025 with $38.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $11.5M -$54.0K -$23.7M -$23.7M $38.3M —
FY2024 (FY) 2024-12-31 $11.7M -$39.3K -$29.4M -$29.4M $53.4M —
FY2023 (FY) 2023-12-31 $9.8M -$41.9K -$33.2M -$33.2M — —

3. JAGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JAGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.88 (-45.43% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, JAGX ranks #871 in composite RQD confidence.

How does JAGX compare to HIND and BOLT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while JAGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JAGX?

Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JAGX trading relative to its 50-day, 200-day, and 52-week technical levels?

JAGX last traded at $0.88 (-45.43% on volume of 2,204,041 shares), positioning the stock -85.33% below its 50-day simple moving average ($6.00) and -99.23% below its 200-day simple moving average ($114.36). Across its 52-week range of $1.60 to $1,102.50, JAGX sits at the 0.0% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

Direct Sub-Reports: JAGX RQD Cockpit JAGX 12M Forecast JAGX Earnings & Move JAGX Dividends & DRIP JAGX Insiders & 13F JAGX Whale Options JAGX Profit Sankey JAGX News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

JAGX — Jaguar Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Jaguar Health Inc. (JAGX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.88 (-45.43% 1D, market capitalization $12.6M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 67.2%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Jaguar Health Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The sources do not describe its specific products, customers, or revenue model beyond the sector classification and the catalyst headline referencing a crofelemer intestinal failure program and an MVID NDA filing target. FY 2025 revenue was $11.5M against an operating loss of -$45.9M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jaguar Health Inc. (JAGX) reported $11.5M in annual revenue (up from $11.7M in FY2024, -1.5% YoY) and -$54.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.8M revenue, -$41.9K net income) through FY2025, JAGX scaled operating cash flow to -$23.7M and free cash flow to -$23.7M, backed by $38.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.60 – $1,102.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlations beyond the Beta of 1.0 are — The second-order item to watch is the interaction between the negative free cash flow reported in each period and the preferred-share special dividend, since dilution or capital-structure changes can alter the funding need implied by the reported cash balance.

  • Key Question #1: Can JAGX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $11.5M and free cash flow of -$23.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is JAGX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

JAGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Jaguar Health Inc. (JAGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JAGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JAGX Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JAGX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on JAGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.04 (+25.9%)
📌 Pinned Debate

JAGX (E • RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.62

Long JAGX at $1.62 targeting $2.04. JAGX (E • RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.62. Institutional whale score is 3/20 and the risk/reward vs. the $1.60 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $1.62 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.23 (-24.1%)
Spot @ $1.62

Negative free cash flow of -$23.7M in FY 2025 against only $1.0M of reported cash, with a Piotroski F-Score of 1/9, signals a funding g

Here is the bear case nobody on the bull side wants to address on JAGX: Negative free cash flow of -$23.7M in FY 2025 against only $1.0M of reported cash, with a Piotroski F-Score of 1/9, signals a funding gap.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%